Trial of THEO-260 in Ovarian Cancer Patients
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
| Condition(s) | Ovarian Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity. |
| Who can participate | Inclusion Criteria: * Confirmed histological diagnosis of advanced high grade serous or endometrioid cancer of the fallopian tube, primary peritoneum or ovary either on archival biopsy or fresh tumour biopsy. * Platinum-resistant disease (radiological recurrence/ progression with 6 months of prior platinum treatment), primary platinum-refractory disease (recurrence/ progression during first line platinum treatment) and patients who are intolerant to or have no available SOC or SOC unacceptable/ unsuitable in the view of the Investigator. * Life expectancy of \> 3 months. * ECOG performance status of 0 or 1. * Measurable disease as per RECIST V1.1. Exclusion Criteria: * Prior anti-cancer treatment within 28 days or 5 half-lives, prior to first dose of THEO-260. * Prior treatment with a grou |
| Ages | 18 Years |
| Sex | Female |
| Lead sponsor | Theolytics Limited |
| Locations | Madrid, Spain; Glasgow, Scotland, United Kingdom; London, United Kingdom; Oxford, United Kingdom |
| Start date | 2024-09-24 |
| NCT ID | NCT06618235 |
| Official listing | https://clinicaltrials.gov/study/NCT06618235 |